Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.

Sereti I, Gulick RM, Krishnan S, Migueles SA, Palfreeman A, Touzeau-Römer V, Belloso WH, Emery S, Law MG; INSIGHT START Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):456-462. doi: 10.1097/QAI.0000000000002052.

PMID:
31241541
2.

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.

Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M.

Sci Immunol. 2019 Apr 19;4(34). pii: eaau2710. doi: 10.1126/sciimmunol.aau2710.

PMID:
31004012
3.

MAdCAM costimulation through Integrin-α4β7 promotes HIV replication.

Nawaz F, Goes LR, Ray JC, Olowojesiku R, Sajani A, Ansari AA, Perrone I, Hiatt J, Van Ryk D, Wei D, Waliszewski M, Soares MA, Jelicic K, Connors M, Migueles SA, Martinelli E, Villinger F, Cicala C, Fauci AS, Arthos J.

Mucosal Immunol. 2018 Sep;11(5):1342-1351. doi: 10.1038/s41385-018-0044-1. Epub 2018 Jun 6.

4.

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.

Martin MP, Naranbhai V, Shea PR, Qi Y, Ramsuran V, Vince N, Gao X, Thomas R, Brumme ZL, Carlson JM, Wolinsky SM, Goedert JJ, Walker BD, Segal FP, Deeks SG, Haas DW, Migueles SA, Connors M, Michael N, Fellay J, Gostick E, Llewellyn-Lacey S, Price DA, Lafont BA, Pymm P, Saunders PM, Widjaja J, Wong SC, Vivian JP, Rossjohn J, Brooks AG, Carrington M.

J Clin Invest. 2018 May 1;128(5):1903-1912. doi: 10.1172/JCI98463. Epub 2018 Apr 3.

5.

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M.

Immunity. 2016 Nov 15;45(5):1108-1121. doi: 10.1016/j.immuni.2016.10.027.

6.

Class II-Restricted CD8s: New Lessons Violate Old Paradigms.

Migueles SA, Connors M.

Immunity. 2016 Oct 18;45(4):712-714. doi: 10.1016/j.immuni.2016.10.004. Review.

7.

Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size.

Pinzone MR, Graf E, Lynch L, McLaughlin B, Hecht FM, Connors M, Migueles SA, Hwang WT, Nunnari G, O'Doherty U.

J Virol. 2016 Nov 14;90(23):10436-10445. doi: 10.1128/JVI.00242-16. Print 2016 Dec 1.

8.

Multiple Origins of Virus Persistence during Natural Control of HIV Infection.

Boritz EA, Darko S, Swaszek L, Wolf G, Wells D, Wu X, Henry AR, Laboune F, Hu J, Ambrozak D, Hughes MS, Hoh R, Casazza JP, Vostal A, Bunis D, Nganou-Makamdop K, Lee JS, Migueles SA, Koup RA, Connors M, Moir S, Schacker T, Maldarelli F, Hughes SH, Deeks SG, Douek DC.

Cell. 2016 Aug 11;166(4):1004-1015. doi: 10.1016/j.cell.2016.06.039. Epub 2016 Jul 21.

9.

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 601 Study Team.

Sci Transl Med. 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.

PMID:
26702094
10.

IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control.

Popescu I, Pipeling MR, Mannem H, Shah PD, Orens JB, Connors M, Migueles SA, McDyer JF.

J Immunol. 2016 Jan 15;196(2):877-90. doi: 10.4049/jimmunol.1501589. Epub 2015 Dec 11.

11.

Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection.

Cubas R, van Grevenynghe J, Wills S, Kardava L, Santich BH, Buckner CM, Muir R, Tardif V, Nichols C, Procopio F, He Z, Metcalf T, Ghneim K, Locci M, Ancuta P, Routy JP, Trautmann L, Li Y, McDermott AB, Koup RA, Petrovas C, Migueles SA, Connors M, Tomaras GD, Moir S, Crotty S, Haddad EK.

J Immunol. 2015 Dec 15;195(12):5625-36. doi: 10.4049/jimmunol.1501524. Epub 2015 Nov 6.

12.

A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.

DeMaster LK, Liu X, VanBelzen DJ, Trinité B, Zheng L, Agosto LM, Migueles SA, Connors M, Sambucetti L, Levy DN, Pasternak AO, O'Doherty U.

J Virol. 2015 Nov 4;90(5):2165-79. doi: 10.1128/JVI.01913-15.

13.

CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA, Kelly EP, Peterson BA, Johnson SA, Galson E, Poropatich KO, Patamawenu A, Imamichi H, Ober A, Rehm CA, Jones S, Hallahan CW, Follmann DA, Connors M.

EBioMedicine. 2014 Dec 22;2(1):46-58. doi: 10.1016/j.ebiom.2014.12.009. eCollection 2015 Jan.

14.

HIV-1 Treated Patients with Undetectable Viral Loads have Lower Levels of Innate Immune Responses via Cytosolic DNA Sensing Systems Compared with Healthy Uninfected Controls.

Swaminathan S, Sui H, Adelsberger JW, Chen Q, Sneller M, Migueles SA, Kottilil S, Ober A, Jones S, Rehm CA, Lane HC, Imamichi T.

J AIDS Clin Res. 2014 Jun;5(6). pii: 315.

15.

Success and failure of the cellular immune response against HIV-1.

Migueles SA, Connors M.

Nat Immunol. 2015 Jun;16(6):563-70. doi: 10.1038/ni.3161. Review.

PMID:
25988888
16.

Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:37-45. doi: 10.1111/hiv.12232.

17.

Should all research subjects be treated the same?

Brody B, Migueles SA, Wendler D.

Hastings Cent Rep. 2015 Jan-Feb;45(1):17-20. doi: 10.1002/hast.414. No abstract available.

PMID:
25600384
18.

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M.

Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.

19.

CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression.

Tabler CO, Lucera MB, Haqqani AA, McDonald DJ, Migueles SA, Connors M, Tilton JC.

J Virol. 2014 May;88(9):4976-86. doi: 10.1128/JVI.00324-14. Epub 2014 Feb 19.

20.

Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.

Sunshine J, Kim M, Carlson JM, Heckerman D, Czartoski J, Migueles SA, Maenza J, McElrath MJ, Mullins JI, Frahm N.

J Virol. 2014 Jan;88(2):1354-65. doi: 10.1128/JVI.02361-13. Epub 2013 Nov 13.

21.

Evidence for innate immune system activation in HIV type 1-infected elite controllers.

Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, Lempicki R, Migueles SA, Sereti I.

J Infect Dis. 2014 Mar;209(6):931-9. doi: 10.1093/infdis/jit581. Epub 2013 Nov 1.

22.

Isolation of human monoclonal antibodies from peripheral blood B cells.

Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR, Connors M.

Nat Protoc. 2013 Oct;8(10):1907-15. doi: 10.1038/nprot.2013.117. Epub 2013 Sep 12.

23.

Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected].

Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, Shaheen F, Martin JN, Deeks SG, Connors M, Migueles SA, O'Doherty U.

PLoS One. 2013 Aug 7;8(8):e71879. doi: 10.1371/journal.pone.0071879. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/3aa92c3d-b6dd-4c6e-8cee-9587ce80a9c9.

24.

Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.

Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD.

Science. 2013 May 10;340(6133):751-6. doi: 10.1126/science.1233989.

25.

Cytotoxic capacity of SIV-specific CD8(+) T cells against primary autologous targets correlates with immune control in SIV-infected rhesus macaques.

Mendoza D, Migueles SA, Rood JE, Peterson B, Johnson S, Doria-Rose N, Schneider D, Rakasz E, Trivett MT, Trubey CM, Coalter V, Hallahan CW, Watkins D, Franchini G, Lifson JD, Connors M.

PLoS Pathog. 2013 Feb;9(2):e1003195. doi: 10.1371/journal.ppat.1003195. Epub 2013 Feb 28.

26.

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M.

Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18.

27.

Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Mexas AM, Graf EH, Pace MJ, Yu JJ, Papasavvas E, Azzoni L, Busch MP, Di Mascio M, Foulkes AS, Migueles SA, Montaner LJ, O'Doherty U.

AIDS. 2012 Nov 28;26(18):2295-306. doi: 10.1097/QAD.0b013e32835a5c2f.

28.

Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, Hallahan CW, Wong H, Liu B, You L, Scheid J, Kappes JC, Ochsenbauer C, Nabel GJ, Mascola JR, Connors M.

J Virol. 2012 Aug;86(16):8672-80. doi: 10.1128/JVI.00287-12. Epub 2012 Jun 6.

29.

Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O'Connell RJ, O'Doherty U, Chun TW, Connors M, Migueles SA.

Blood. 2012 May 17;119(20):4645-55. doi: 10.1182/blood-2011-10-381996. Epub 2012 Apr 5.

30.

Inhibitory Killer Immunoglobulin-like Receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors.

Kamya P, Tallon B, Melendez-Pena C, Parsons MS, Migueles SA, Connors M, Miconiatis S, Song R, Boulet S, Bruneau J, Tremblay CL, Bernard NF; investigators of the Canadian Cohort of HIV Infected Slow Progressors.

Clin Immunol. 2012 Jun;143(3):246-55. doi: 10.1016/j.clim.2012.01.001. Epub 2012 Jan 15.

PMID:
22445844
31.

Small molecules and big killers: the challenge of eliminating the latent HIV reservoir.

Migueles SA, Connors M.

Immunity. 2012 Mar 23;36(3):320-1. doi: 10.1016/j.immuni.2012.03.006.

32.

HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells.

Mendoza D, Royce C, Ruff LE, Ambrozak DR, Quigley MF, Dang T, Venturi V, Price DA, Douek DC, Migueles SA, Connors M.

J Virol. 2012 Apr;86(7):4014-8. doi: 10.1128/JVI.06982-11. Epub 2012 Jan 25.

33.

Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand.

Jain A, Kovacs JA, Nelson DL, Migueles SA, Pittaluga S, Fanslow W, Fan X, Wong DW, Massey J, Hornung R, Brown MR, Spinner JJ, Liu S, Davey V, Hill HA, Ochs H, Fleisher TA.

Blood. 2011 Oct 6;118(14):3811-7. doi: 10.1182/blood-2011-04-351254. Epub 2011 Aug 12.

34.

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors.

J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6.

35.

CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors.

Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, Hodge JN, Thompson WL, Kovacs SB, Chairez CL, Migueles SA, Kovacs JA, Margolis LB, Sereti I.

J Virol. 2011 Jun;85(12):5880-8. doi: 10.1128/JVI.02643-10. Epub 2011 Apr 6.

36.

Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control.

Hersperger AR, Migueles SA, Betts MR, Connors M.

Curr Opin HIV AIDS. 2011 May;6(3):169-73. doi: 10.1097/COH.0b013e3283454c39. Review.

37.

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.

Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, Patamawenu A, Hallahan CW, Cogliano NA, Frahm N, Duerr A, McElrath MJ, Connors M.

PLoS Pathog. 2011 Feb;7(2):e1002002. doi: 10.1371/journal.ppat.1002002. Epub 2011 Feb 24.

38.

Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.

Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, Migueles SA, Connors M, O'Doherty U.

PLoS Pathog. 2011 Feb;7(2):e1001300. doi: 10.1371/journal.ppat.1001300. Epub 2011 Feb 24. Erratum in: PLoS Pathog. 2011 Mar;7(3). doi: 10.1371/annotation/0d21de23-d44c-49c0-9a9f-53d421648cbf.

39.
40.

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.

Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M.

J Virol. 2010 Feb;84(3):1631-6. doi: 10.1128/JVI.01482-09. Epub 2009 Nov 18.

41.

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT Jr, Connors M.

J Virol. 2009 Nov;83(22):11876-89. doi: 10.1128/JVI.01153-09. Epub 2009 Sep 2.

42.

Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.

Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT Jr, Connors M, Migueles SA.

J Virol. 2009 Mar;83(6):2728-42. doi: 10.1128/JVI.02128-08. Epub 2009 Jan 7.

43.

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.

Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M.

Immunity. 2008 Dec 19;29(6):1009-21. doi: 10.1016/j.immuni.2008.10.010. Epub 2008 Dec 8.

44.

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.

45.

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.

46.

Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Pipeling MR, West EE, Osborne CM, Whitlock AB, Dropulic LK, Willett MH, Forman M, Valsamakis A, Orens JB, Moller DR, Lechtzin N, Migueles SA, Connors M, McDyer JF.

J Immunol. 2008 Jul 1;181(1):546-56.

47.

Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR.

Nat Med. 2007 Sep;13(9):1032-4. Epub 2007 Aug 26.

48.

CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro.

Kinter AL, Horak R, Sion M, Riggin L, McNally J, Lin Y, Jackson R, O'shea A, Roby G, Kovacs C, Connors M, Migueles SA, Fauci AS.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):438-50.

PMID:
17411377
49.

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA.

Blood. 2006 Jun 15;107(12):4781-9. Epub 2006 Feb 7.

50.

Qualitative host factors associated with immunological control of HIV infection by CD8 T cells.

Migueles SA, Tilton JC, Connors M.

Curr Opin HIV AIDS. 2006 Jan;1(1):28-33. doi: 10.1097/01.COH.0000194108.14601.69.

PMID:
19372780

Supplemental Content

Loading ...
Support Center